Research progress and challenges of neoadjuvant therapy for esophageal squamous cell carcinoma.
10.3760/cma.j.cn.441530-20201207-00647
- Author:
Hong Dian ZHANG
1
;
Hua Gang LIANG
2
;
Peng TANG
1
;
Zhen Tao YU
3
Author Information
1. Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, Clinical Research Center for Cancer, Tianjin 300060, China.
2. Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, Clinical Research Center for Cancer, Tianjin 300060, China Department of Thoracic Surgery, the First Hospital of Qinhuangdao, Hebei 066000, China.
3. Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, Clinical Research Center for Cancer, Tianjin 300060, China Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.
- Publication Type:Systematic Review
- Keywords:
Esophageal squamous cell carcinoma;
Immunotherapy;
Neoadjuvant therapy
- MeSH:
Chemoradiotherapy;
Combined Modality Therapy;
Esophageal Neoplasms/surgery*;
Esophageal Squamous Cell Carcinoma/therapy*;
Esophagectomy;
Humans;
Neoadjuvant Therapy
- From:
Chinese Journal of Gastrointestinal Surgery
2021;24(9):836-842
- CountryChina
- Language:Chinese
-
Abstract:
Surgery is the main treatment for resectable esophageal squamous cell carcinoma. However, for patients with locally advanced lesions, surgery-based comprehensive treatment is the best treatment strategy. According to the results of some randomized controlled clinical studies and meta-analysis, preoperative neoadjuvant therapy is recommended to improve the survival rate of patients. Neoadjuvant therapy includes neoadjuvant chemotherapy, chemoradiotherapy, targeted therapy and immunotherapy. Great progress has been made in neoadjuvant therapy, but there are still many clinical problems that need to be solved urgently, including the efficacy and safety of neoadjuvant therapy, the choice of neoadjuvant regimen and treatment cycle, the best combination and advantages of multimodal treatment, and the selection of responders to treatment, etc. This article provides a systematic review of the latest developments and existing controversies in neoadjuvant therapy for esophageal squamous cell carcinoma.
